Navigation Links
UTMB named a World Health Organization Collaborating Center for Vaccine Research
Date:8/15/2014

The world experts on vaccine development at the University of Texas Medical Branch at Galveston have received an international designation acknowledging their unique niche in a sphere where research, government regulation and big pharma often collide.

UTMB's Sealy Center for Vaccine Development has been named a World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases. The designation by WHO makes UTMB only the second university in the Western Hemisphere to receive this designation; the other is the Johns Hopkins Bloomberg School of Public Health.

This means that UTMB's vaccine development experts will collaborate with a select team of international experts to help facilitate vaccine research and development against important infectious diseases for example, figuring out how to get experimental Ebola vaccine candidates to suffering people in the wake of the recent outbreak.

"UTMB's top-tier expertise in vaccine development is acknowledged among scientists across the globe," said Joachim Hombach, senior adviser, Immunization, Vaccines and Biologicals at WHO and co-director of the Global Vaccine and Immunization Research Forum. "Especially regarding emerging infectious diseases that represent a significant cause of suffering and death, and impose an enormous financial burden on society, UTMB is clearly recognized as one of the most important international leaders in the vaccine development world."

The medical branch is only the seventh university in the world to receive WHO designation for vaccine expertise. In addition to the Johns Hopkins Bloomberg School of Public Health, the others are the University of Geneva, University of Zurich, and University of Lausanne in Switzerland, the Second Military Medical University in Shanghai and the University of Antwerp in Belgium.

"UTMB fills a critical role at the intersection of biocontainment and emerging diseases and the regulatory hurdles and processes you have to go through to get product approval even in the case of urgent, unmet needs," said UTMB's David Beasley, associate professor of microbiology and immunology and associate director of the UTMB WHO Collaborating Center for Vaccine Research.

UTMB is the only academic institution in the United States with a fully operational biosafety level four containment facility the Galveston National Laboratory where research on the world's most deadly pathogens can be conducted under the strictest safety practices and procedures.

WHO Collaborating Centers support WHO to investigate public health issues from many angles, ranging from basic science and animal studies to clinical trials, public policy, training and funding.

"UTMB is uniquely positioned as an academic center to sit between the regulating agencies and the public health agencies," said Alan Barrett, director of the UTMB Sealy Center for Vaccine Development and director of the UTMB WHO Collaborating Center for Vaccine Research. "We bring our perspective as scientists to the table at these global discussions where critical policies and processes to address emerging infectious disease threats are formulated."

UTMB's responsibilities will be to track and provide analysis of the vaccine pipeline against emerging infectious diseases, to conduct research on the development, evaluation and use of vaccines against emerging infectious diseases of public health importance, and to provide education and training for future investigators in the field of vaccinology.


'/>"/>

Contact: Molly Dannenmaier
mjdannen@utmb.edu
409-772-8790
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related biology news :

1. UTHealths Dr. William Margolin named distinguished lecturer for microbiology
2. UH professor named 2014 American Chemical Society Cope Scholar
3. California State Senator Darrell Steinberg named as ESA Regional Policy Award winner
4. New mite species from a Caribbean mesophotic coral ecosystem named after J.Lo
5. Arizona State faculty member named Howard Hughes Medical Institute Professor
6. Victor Ambros named co-recipient of 2014 Gruber Genetics Prize
7. New grasshopper species named after Grammy winner
8. ICRAF scientist named AfriCAN Climate Research Award winner
9. UH student named Goldwater Scholar, 2 more receive honorable mention
10. Orchid named after UC Riverside researcher
11. Energy Systems Integration Facility named Lab of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
(Date:1/19/2017)... Research and Markets has announced the addition ... Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... is projected to reach $15,737 million by 2022 from $6,521 in ... Omic technologies segment accounted for more than half ...
(Date:1/19/2017)... and HOUSTON , Jan. 19, ... today announced the formation of its Medical/Clinical Advisory ... and industry veterans who enhance the range and ... accelerates development of its novel prenatal diagnostic tests.  ... clinical and strategic guidance for the company,s product ...
Breaking Biology Technology: